Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should KnowZacks Investment Research • 01/25/23
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas' iNK Cell Franchise and Related Gene Editing TechnologiesGlobeNewsWire • 01/19/23
Editas Medicine, Inc. (EDIT) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/11/23
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell DiseaseGlobeNewsWire • 12/06/22
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell DiseaseGlobeNewsWire • 12/01/22
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE TrialGlobeNewsWire • 11/17/22